Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Profit After Tax: 2017-2024

Historic Profit After Tax for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$543.3 million.

  • BridgeBio Pharma's Profit After Tax fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$805.7 million, marking a year-over-year decrease of 80.53%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Profit After Tax of -$543.3 million as of FY2024, which was up 16.82% from -$653.3 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Profit After Tax high stood at -$484.7 million for FY2022, and its period low was -$653.3 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Profit After Tax value was -$543.3 million (recorded in 2024), while the average stood at -$560.4 million.
  • Per our database at Business Quant, BridgeBio Pharma's Profit After Tax tumbled by 75.16% in 2020 and then rose by 17.36% in 2022.
  • BridgeBio Pharma's Profit After Tax (Yearly) stood at -$505.5 million in 2020, then fell by 16.02% to -$586.5 million in 2021, then grew by 17.36% to -$484.7 million in 2022, then plummeted by 34.79% to -$653.3 million in 2023, then rose by 16.82% to -$543.3 million in 2024.